Arcadia Biosciences
RKDA
14 hedge funds and large institutions have $2.72M invested in Arcadia Biosciences in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.05% less ownership
Funds ownership: 0.19% → 0.14% (-0.05%)
12% less capital invested
Capital invested by funds: $3.1M → $2.72M (-$378K)
22% less funds holding
Funds holding: 18 → 14 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$502K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$175K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$94.3K |
| 4 |
VF
Virtu Financial
New York
|
+$55.6K |
| 5 |
Morgan Stanley
New York
|
+$43.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$928K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$234K |
| 3 |
BAM
Blueshift Asset Management
Red Bank,
New Jersey
|
-$138K |
| 4 |
Squarepoint
New York
|
-$124K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$77K |
RKDA Hedge Fund Activity: Q4 2019 in Review
14 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q4 2019, worth a combined $2.72M — down 12% from $3.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RKDA and 5 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Ardsley Advisory Partners, opening a new position worth an estimated $502K. The largest seller was D.E. Shaw & Co, cutting an estimated $928K.
- 14 institutional investors held Arcadia Biosciences (RKDA) as of Q4 2019, down from 18 in Q3 2019.
- Funds reported $2.72M of Arcadia Biosciences stock for Q4 2019, down 12% quarter-over-quarter.
- 5 funds opened new Arcadia Biosciences positions in Q4 2019 and 9 closed out, a net change of -4 holders.
- The largest Arcadia Biosciences buyer in Q4 2019 was Ardsley Advisory Partners, an estimated $502K added.
- The largest Arcadia Biosciences seller in Q4 2019 was D.E. Shaw & Co, an estimated $928K sold.
Based on aggregated 13F filings for Q4 2019.